Literature DB >> 28178607

Family history of cancer other than breast or ovarian cancer in first-degree relatives is associated with poor breast cancer prognosis.

Jun-Long Song1, Chuang Chen1, Jing-Ping Yuan2, Juan-Juan Li1, Sheng-Rong Sun3.   

Abstract

OBJECTIVE: Whether a first-degree family history of others cancers (FHOC) than breast or ovarian cancer (BOC) is associated with breast cancer prognosis remains unknown. Thus, the aim of the present study was to clarify this issue.
METHODS: Women who were diagnosed with invasive breast cancer at the Renmin Hospital of Wuhan University from 2010 to 2013 were included in the study. The demographic and clinicopathological characteristics of these patients were extracted. FHOC was considered positive for any patient who had a relative who had been diagnosed with cancer other than BOC. Disease-free survival (DFS) was calculated based on the date of diagnosis. DFS was analyzed using the Cox proportional hazards model.
RESULTS: A total of 434 breast cancer patients were included in this study. Among these patients, 61 (14.06%) had a positive FHOC in first-degree relatives. Patients with a positive FHOC tended to have HER2-positive breast cancer (p = 0.03). In the survival analysis, FHOC was associated with poor DFS in both univariate (HR = 2.21 (1.28-3.83), 95% CI: 1.28-3.83, p < 0.01) and multivariate (HR = 2.50, 95% CI: 1.24-5.04, p = 0.01) analyses, especially in patients with luminal A subtypes.
CONCLUSION: The results demonstrated an increased risk of recurrence in breast cancer patients with FHOC, especially in patients with luminal A subtype.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Disease-free survival; Family history of other cancer; Prognosis

Mesh:

Substances:

Year:  2017        PMID: 28178607     DOI: 10.1016/j.breast.2017.01.016

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  4 in total

Review 1.  [Genital metastases from breast cancer: study of 3 cases and literature review].

Authors:  Olfa Zoukar; Anis Haddad; Amira Daldoul; Sonia Zaied; Amina Ben Salem; Ines Zouari; Raja Faleh
Journal:  Pan Afr Med J       Date:  2018-05-04

2.  Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.

Authors:  Alessio Cortellini; Sebastiano Buti; Melissa Bersanelli; Raffaele Giusti; Fabiana Perrone; Pietro Di Marino; Nicola Tinari; Michele De Tursi; Antonino Grassadonia; Katia Cannita; Alessandra Tessitore; Federica Zoratto; Enzo Veltri; Francesco Malorgio; Marco Russano; Cecilia Anesi; Tea Zeppola; Marco Filetti; Paolo Marchetti; Andrea Botticelli; Gian Carlo Antonini Cappellini; Federica De Galitiis; Maria Giuseppa Vitale; Francesca Rastelli; Federica Pergolesi; Rossana Berardi; Silvia Rinaldi; Marianna Tudini; Rosa Rita Silva; Annagrazia Pireddu; Francesco Atzori; Daniela Iacono; Maria Rita Migliorino; Alain Gelibter; Mario Alberto Occhipinti; Francesco Martella; Alessandro Inno; Stefania Gori; Sergio Bracarda; Cristina Zannori; Claudia Mosillo; Alessandro Parisi; Giampiero Porzio; Domenico Mallardo; Maria Concetta Fargnoli; Marcello Tiseo; Daniele Santini; Paolo A Ascierto; Corrado Ficorella
Journal:  Oncoimmunology       Date:  2020-01-07       Impact factor: 8.110

3.  Correlation between family history and characteristics of breast cancer.

Authors:  Lei Liu; Xiaomeng Hao; Zian Song; Xiangcheng Zhi; Sheng Zhang; Jin Zhang
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

4.  Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials.

Authors:  Yaqian Xu; Yanping Lin; Yaohui Wang; Liheng Zhou; Shuguang Xu; Yifan Wu; Jing Peng; Jie Zhang; Wenjin Yin; Jinsong Lu
Journal:  EClinicalMedicine       Date:  2021-07-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.